Pharmaceuticals Search Engine [selected websites]


Monday, June 4, 2012

Provence Technologies and Neuroptis Biotech partner to develop a new compound for treating dry eye syndrome

Neuroptis Biotech Marseille, France, and Paris, France, 21 May, 2012 - Provence Technologies to optimize and transfer the production process for ML7, Neuroptis Biotech’s dry eye drug candidate

Provence Technologies, a service provider of specialist fine chemistry, and Neuroptis Biotech, specializing in the discovery and development of innovative therapies in neurology and ophthalmology, announce today the further strengthening of their collaboration for transferring the chemical development of Neuroptis Biotech’s drug candidate, ML7, and producing the first GMP batches before the end of 2012.

Provence TechnologiesML7 is a drug candidate for the treatment of dry eye syndromes. It is the first of a new therapeutic class and has the potential to provide a targeted and effective therapeutic remedy for the millions of people suffering from dry eye syndrome, Gougerot-Sjögren syndrome, and inflammations, especially ones caused by allergies. Provence Technologies and Neuroptis Biotech have already collaborated successfully in developing a synthetic pathway for ML7, manufacturing the first non-GMP batches, and devising associated analytical methods. The two companies have embarked on the process optimization phase to facilitate the transfer of the compound and the start of production on an industrial scale, scheduled for September this year... [PDF] Provence Technologies' Press Release - Neuroptis Biotech's Press Release - [PDF] Communiqué de Presse de Provence Technologies -